Autoimmune Disease Therapeutics Market is expected to grow at a value of US$ 1,17,967.44 million by 2032

Autoimmune diseases is a body’s hyperactive immune response against the substances and tissues normally present in the body. Autoimmune diseases are more commonly caused by genetic, infectious or environmental factors. The prevalence of autoimmune disease is on rise. According to National Institute of Health, approximately 50 million of Americans suffer from autoimmune diseases.

The market for Autoimmune Disease Therapeutics Market is expected to reach US$ 68,410.54 million in 2022 and grow at a moderate rate of 5.6% CAGR over the same period. By 2032, the market is projected to increase in size and reach US$ 1,17,967,44 million. According to Future Market Insights’ data, the historical CAGR was 4.8%.

There are more than 80 different types of autoimmune disorders, with multiple sclerosis, irritable bowel syndrome (IBS), lupus, type 1 diabetes, psoriasis, rheumatoid arthritis, and others being the most prevalent.

The diseases in estimated to be one of the top 10 cause of death in women under the age 65, and is the second highest cause of chronic illness. Also, it is the top cause of morbidity in women in the U.S. There are more than 80 clinically different type of autoimmune diseases identified till date. Some of the common types of autoimmune diseases are Crohn’s disease, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, and with rising prevalence of autoimmune diseases the demand of drugs used in the treatment for autoimmune disease is also rising.

The global market for autoimmune disease therapeutics is expected to have a robust growth during the forecast period (2016–2026).

Autoimmune Disease Therapeutics Market: Drivers and Restraints

Factors contributing to the growth of global autoimmune disease therapeutics market includes, growing prevalence of autoimmune diseases coupled with growing public awareness and increasing automation of laboratories leading to diagnosis of several diagnostic tests simultaneously to generate rapid and error free results. In addition, technological advancements such as the development of novel biomarkers such as Enbrel and Humira, and portable diagnostic point of care equipment are further expected to fuel the market growth in the near future. However, factors such as, inadequate funding in developing countries, high cost involved in the treatment of the disease and non-availability of the treatment in developing countries along with emergence of alternative technologies are the main restraints for the global autoimmune disease therapeutics market.

Autoimmune disease therapeutics Market: Overview

With rising incidence of autoimmune diseases, rapid technological advancements in medical field such as novel biomarkers, rise in healthcare expenditure, development and presence of large untapped opportunities in the emerging markets such as Eastern European, APAC and MEA region are major factors, expected to boost the growth of the global autoimmune disease therapeutics market during the forecast period (2016–2026).

To remain ‘ahead’ of your competitors, request for a sample @ 
https://www.futuremarketinsights.com/reports/sample/rep-gb-1238

Autoimmune Disease Therapeutics Market: Region-wise Outlook

The global market for autoimmune disease therapeutics is expected to register a healthy CAGR during the forecast period. Depending on geographic regions, global autoimmune disease therapeutics market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

North America accounts for the largest market shares in the autoimmune disease therapeutics market owing to growing prevalence of various forms of autoimmune disorders, and presence of government initiatives such as Affordable Care Act and Patient Protection Act.  Increasing healthcare expenditure in the region is also expected to drive the overall autoimmune disease therapeutics market in the near future. According to National Institute of Health estimates in the U.S. the annual expenditure on autoimmune disease therapeutics is estimated to be US$ 100 Bn. Europe is anticipated to be the second largest market during the forecast period owing to increasing government with the focus of improving healthcare infrastructure, growing prevalence of autoimmune diseases, increased penetration of new technologies such as portable diagnostic equipment and novel biomarkers. However, in Eastern Europe presence of large untapped opportunities will fuel the market growth of autoimmune disease therapeutics in the coming years.

Autoimmune disease therapeutics Market: Key Players

Some of the key market players in global autoimmune disease therapeutics market are Abbott Laboratories, Amgen Inc., Genentech Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer Schering Pharma AG, Johnson & Johnson Inc., Biogen Idec Inc., GlaxoSmithKline Plc, Squibb Company, Elan Corporation Plc, Eli Lilly and Company, Chugai Pharmaceutical Co. Ltd.

Ask An Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-1238

Why Future Market Insights?

  •   Comprehensive analysis on evolving purchase pattern across different geographies
  •   Detailed insights of market segments and sub-segments for historical as well as forecast period
  •   A competitive analysis of prominent players and emerging players in the keyword market
  •   Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Key Segments In The Autoimmune Disease Therapeutics Market

By Drug Class Type:

  • Anti-inflammatory
  • Antihyperglycemics
  • NSAIDs
  • Interferons
  • Others

By Indication:

  • Rheumatic Disease
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Other Indications

By Sales Channel:

  • Hospital Pharmacy
  • Drug Store & Retail Pharmacy
  • Online Store

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Request Customization @ 
https://www.futuremarketinsights.com/customization-available/rep-gb-1238

About Us

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiriessales@futuremarketinsights.com
Websitehttps://www.futuremarketinsights.com
LinkedInTwitterBlogs

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these